PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Cited by (622)

Items 301–400 of 622

1. Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
   Yaru Tian, Xiaoyang Zhai, Hairong Tian, Jing Wang, Hui Zhu, Jinming Yu · 2019 · Cancer Management and Research
2. Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry
   Kristián Brat, Monika Bratová, Jana Skřičková, Magda Bařinová, Karolina Hurdalkova, Miloš Pešek, Libor Havel, Leona Koubková, Michal Hrnčiarik, Jana Krejčí et al. · 2020 · Thoracic Cancer
3. Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
   Jianjie Li, Yujia Chi, Guang Cao, Jun Zhao, Tongtong An, Meina Wu, Yuyan Wang, Minglei Zhuo, Xue Yang, Bo Jia et al. · 2021 · Journal of Thoracic Disease
4. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non‐small cell lung cancer: A meta‐analysis of randomized controlled trials
   Miaowen Liu, Nachuan Luo, Zige Fang, Qiangyun Liu, Fengming Yi, Yiping Wei, Xinyi Zhang, Wenxiong Zhang · 2021 · Journal of Clinical Pharmacy and Therapeutics
5. EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis
   Mohan Liu, Kaiwen Xiao, Li Yang · 2023 · International Immunopharmacology
6. Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809
   Seiji Niho, Norihiko Ikeda, Hirofumi Michimae, Kenji Suzuki, Hiroshi Sakai, T Kaburagi, Koichi Minato, Terufumi Kato, Hiroaki Okamoto, Takashi Seto et al. · 2013 · British Journal of Cancer
7. Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer
   Minglei Zhuo, Hua Bai, Zhijie Wang, Jianchun Duan, Tongtong An, Meina Wu, Jun Zhao, Yuyan Wang, Shuhang Wang, Jie Wang · 2014 · Molecular and Clinical Oncology
8. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
   David Felix Heigener, José Rodrigues Pereira, Enriqueta Felip, Juraj Mazal, Lyudmila Manzyuk, Eng Huat Tan, Ofer Merimsky, Barbara Sarholz, Regina Esser, Ulrich Gatzemeier · 2014 · Targeted Oncology
9. eCROPS-CA: a systematic approach toward effective and sustainable cancer prevention in rural China
   Jing Chai, Xingrong Shen, Rui Feng, Jing Cheng, Yeji Chen, Zhengqiu Zha, Shangchun Jia, Han Liang, Ting Zhao, Rui Sha et al. · 2015 · BMC Cancer
10. Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
    Di Ma, Xuezhi Hao, Yan Wang, Puyuan Xing, Junling Li · 2016 · Thoracic Cancer
11. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
    Liping Lin, Juanjuan Zhao, Jiazhu Hu, Fuxi Huang, Jianjun Han, Yan He, Xiaolong Cao · 2016 · OncoTargets and Therapy
12. Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC
    Nikhil Atul Shukla, Nasser H. Hanna, Greg Andrew Durm · 2021 · JCO Oncology Practice
13. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer
    Jared M. Weiss, Liza Cosca Villaruz, Jonathon J. O’Brien, Anastasia Ivanova, Carrie B. Lee, Juneko Grilley Olson, Gregory Pollack, Richard Gorman, Mark A. Socinski, Thomas E. Stinchcombe · 2015 · Clinical Lung Cancer
14. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature
    Yassir Sbitti, Hafsa Chahdi, Khaoula Alaoui Slimani, Adil Debbagh, Anouar Mokhlis, A. Albouzidi, Fahd Bennani, Hassan H Errihani, Mohamed Ichou · 2017 · Journal of Medical Case Reports
15. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
    Yoshihiro Hattori, Yuko Kono, Shoichi Itoh, Takako Inoue, Yoshiko Urata, Yoshitaka Kawa, Rie Tohnai, Toru Kumagai, Kazumi Nishino, Ryuji Uozumi et al. · 2020 · BMC Cancer
16. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
    Giuseppe Bronte, Tindara Franchina, Massimiliano Alù, Giovanni Sortino, Claudia Celesia, Francesco Passiglia, Giuseppina Savio, Agata Laudani, Alessandro Russo, Antonio Picone et al. · 2016 · Oncotarget
17. Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report
    Sang Mi Chung, Seong Ji Choi, Min-Jeong Kim, Jung Yoon Choi, Hong Jun Kim, Suk‐young Lee, Eun Joo Kang · 2016 · Oncology Letters
18. Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer
    Minehiko Inomata, Kazuki Shimokawa, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Tōru Yamada, Toshiro Miwa, Ryuji Hayashi, Tatsuhiko Kashii et al. · 2016 · Anticancer Research
19. Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non–Small-cell Lung Cancer: A Multicenter Italian Survey
    Maria Vittoria Pacchiana, Enrica Capelletto, Simona Carnio, Cesare Gridelli, Antônio Rossi, Domenico Galetta, Elisabetta Sara Montagna, Paola Bordi, Anna Ceribelli, Diego Luigi Cortinovis et al. · 2016 · Clinical Lung Cancer
20. Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
    Alessio Cortellini, Elisabetta Gambale, Katia Cannita, Davide Brocco, Alessandro Parisi, Luca Napoleoni, Francesco Masedu, Luciana Irtelli, Michele De Tursi, Clara Natoli et al. · 2017 · Thoracic Cancer
21. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Gary Middleton, Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, Martin Reck, Rodryg Ramlau, Bárbara Parente, Thierry Pieters, Carla Visseren‐Grul, Belén San Antonio et al. · 2018 · Current Medical Research and Opinion
22. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
    Fen Wang, Julian R. Molina, Daniel Satele, Jun Yin, Vun-Sin Lim, Alex A. Adjei · 2018 · Investigational New Drugs
23. Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real-world experience
    Kuruswamy Thurai Prasad, Valliappan Muthu, Bivas Biswas, Prabhat Singh Malik, Deepak Dabkara, Sandip Ganguly, Joydeep Ghosh, Babita Kataria, Sachin Khurana, Saurav Verma et al. · 2020 · Current Problems in Cancer
24. What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?
    Biagio Ricciuti, Mark Magdi Awad · 2020 · The Cancer Journal
25. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario
    Ernest Nadal, Dolores Bautista, Luis Cabezón‐Gutiérrez, Ana Laura Ortega Granados, Héctor Enrique Torres Rivas, David Carcedo, Lucía Ruiz de Alda, J. F. García, Paula Vieitez, Federico Rojo · 2021 · BMC Cancer
26. Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung
    Tetsuya Isaka, Haruhiko Nakayama, Tomoyuki Yokose, Hiroyuki Ito, Kayoko Katayama, Kouzo Yamada, Munetaka Masuda · 2016 · Annals of Thoracic and Cardiovascular Surgery
27. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Yamin Shu, Yiling Ding, Feie Li, Qilin Zhang · 2022 · International Immunopharmacology
28. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China
    Meiling Zhang, Bei Zheng, Wenjuan Yang, Hong Jiang, Xueshan Sun, Zixuan Zhao, Gonghua Li, Hengjin Dong · 2024 · Clinical Medicine Insights Oncology
29. Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
    Diego Signorelli, Marianna Macerelli, Claudia Proto, Milena Vitali, Maria Silvia Cona, Francesco Agustoni, Nicoletta Zilembo, Marco Platania, Annalisa Trama, Rosaria Gallucci et al. · 2015 · Tumori Journal
30. Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
    Avinash Pandey, Deepa Susan Phillip, Vanita Noronha, Amit Joshi, Amit Janu, Nirmala Jambekar, Rajesh Kaushal, Abhishek Mahajan, Kumar Prabhash · 2015 · Indian Journal of Medical and Paediatric Oncology
31. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy
    Min Yang, Weifei Fan, Xiaolin Pu, Lijuan Meng, Jun Wang · 2016 · Journal of Chemotherapy
32. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
    Jaclyn Marie Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew George Robinson, Elena Mow, James M. Keech, Kelvin Chan · 2021 · BMC Cancer
33. Quality of Care of Patients with Non–Small-Cell Lung Cancer: A Report of a Performance Improvement Initiative
    Fred R. Hirsch, Robert M. Jotte, Carolyn A. Berry, William A. Mencia, Stephanie A. Stowell, Allison J. Gardner · 2014 · Cancer Control
34. Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site
    Tindara Franchina, Alessandro Russo, Giuseppina Rosaria Rita Ricciardi, Giuseppina Liguori, Astrid Herberg, Nicola Normanno, Vincenzo Adamo · 2016 · Cancer Biology & Therapy
35. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients
    Laura Mezquita, Mélinda Charrier, Laura Faivre, Louise Dupraz, Beranger Lueza, Jordi Remón, David Planchard, Maria Virginia Bluthgen, Francesco Facchinetti, Arslane Skander Rahal et al. · 2017 · Lung Cancer
36. Chemotherapy Immunophenoprofiles in Non‐Small‐Cell Lung Cancer by Personalized Membrane Proteomics
    Denise Utami Putri, Po‐Hao Feng, Yuu‐Hueih Hsu, Kang‐Yun Lee, Feng‐Wen Jiang, Lu-Wei Kuo, Yu‐Ju Chen, Chia‐Li Han · 2017 · PROTEOMICS - CLINICAL APPLICATIONS
37. Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience
    P Paliwal, Senthill J Rajappa, Santa Ayyagari, M. V. T. Krishna Mohan, Sudha Murthy, N Lavanya · 2017 · Indian Journal of Cancer
38. Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer
    Anant Ramaswamy, Vikas S. Ostwal, Subhadeep Bose, Bhawna Sirohi, Bhavesh Pradip Poladia, Arvind Sahu, PRABHAT GHANSHYAM BHARGAVA, Vipul Doshi, Rohit Dusane, Chaitali Nashikkar et al. · 2018 · Indian Journal of Cancer
39. Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD
    Weigang Dong, Yan Du, Shuping Ma · 2018 · International Journal of COPD
40. Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
    Joon‐Young Yoon, Cheol‐Kyu Park, Yoo Duk Choi, In‐Jae Oh, Young‐Chul Kim · 2019 · Thoracic Cancer
41. Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
    Takashige Abe, Keita Minami, Toru Harabayashi, Ataru Sazawa, Hiroki Chiba, Hiroshi Kikuchi, Haruka Miyata, Ryuji Matsumoto, Takahiro Osawa, Satoru Maruyama et al. · 2019 · Japanese Journal of Clinical Oncology
42. Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)
    Ping‐Chih Hsu, Chien‐Ying Liu, Shih‐Hong Li, Shih-How Huang, Chih‐Liang Wang, Chih‐Hsi S. Kuo, Fu‐Tsai Chung, Chih‐Hung Chen, Chih‐Teng Yu, Cheng‐Ta Yang · 2016 · Cancer Treatment and Research Communications
43. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed
    Ondřej Fiala, Petr Hošek, Miloš Pešek, Jindřich Fínek, J. Racek, Tomáš Büchler, Alexandr Poprach, Karel Hejduk, Renata Chloupková, Ondřej Šorejs et al. · 2017 · Neoplasma
44. Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer
    Jerome H. Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L. Santorelli, Thomas W. Burke, Nathan A. Pennell · 2024 · Immunotherapy
45. Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
    Kang Wang, Zhenxue Fu, Guanxing Sun, Yancui Ran, Nannan Lv, Enbo Wang, Huan Ding · 2024 · BMC Immunology
46. Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration
    Hirva Mansurali Mamdani, Shadia Ibrahim Jalal, Nasser H. Hanna · 2015 · Current Treatment Options in Oncology
47. Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous non-small cell lung cancer.
    Seigo Minami, Takashi Kijima, Kiyoshi Komuta, Toru Kumagai, Fumio Imamura, Soichiro Yokota, Yoshiko Takeuchi, Takeshi Nakatani, Isao Tachibana, Ichiro Kawase · 2013 · PubMed
48. Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives
    Francesco Petrella, Isabella Rimoldi, Giorgio Facchetti, Lorenzo Spaggiari · 2018 · Expert Opinion on Therapeutic Patents
49. Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies
    Edward B. Garon, Patrick M. Peterson, Maria Teresa Rizzo, Jong Seok Kim · 2021 · Clinical Lung Cancer
50. Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
    Jia Li, Baohui Han, Huaimin Liu · 2022 · Frontiers in Oncology
51. Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer
    Tomohiro Tamura, Koichi Kurishima, Kensuke Nakazawa, Hiroichi Ishikawa, Hiroaki Satoh, Nobuyuki Hizawa · 2015 · Oncology Letters
52. How much platinum-based chemotherapy is enough in NSCLC?
    Solange Peters, Alex A. Adjei · 2014 · Nature Reviews Clinical Oncology
53. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer
    Qin Zhang, Xuwei Cai, Zheng-Fei Zhu, Wen Juan Yu, Qi Liu, Wen Feng, Xue Mengchen, Xiaolong Fu · 2015 · Anti-Cancer Drugs
54. NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status
    Grace Kho Dy, Julian R. Molina, Yingwei Qi, Rafat Ansari, Sachdev P. Thomas, Helen J. Ross, Gamini S. Soori, Daniel Anderson, Marie Christine Aubry, Jeffrey P. Meyers et al. · 2014 · Journal of Thoracic Oncology
55. Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
    Normand Blais, Vera Hirsh · 2014 · Frontiers in Oncology
56. An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer
    Lühua Wang, Yi-Long Lung Cancer Wu, Shun Lü, Lei Deng, Myung‐Ju Ahn, Feng‐Ming Hsu, Neill Iscoe, Anwar Hossain, Tarun Puri, Pinghai Zhang et al. · 2016 · Asia-Pacific Journal of Clinical Oncology
57. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models
    Nobuyuki Ishikura, MIEKO YANAGISAWA, Mariko Noguchi‐Sasaki, TOSHIKI IWAI, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Kaname Yamamoto · 2017 · Anticancer Research
58. First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)
    David Robert Spigel, Tarek M. Mekhail, David Michael Waterhouse, Terence J. Hadley, Charles D. Webb, Howard A. Burris, John Daniel Hainsworth, F. Anthony Greco · 2017 · Cancer Investigation
59. Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
    Lin Zhong, Weize Lv, Siyang Wang, Jinlin Zou, Yun-Yan Con, Zhi-Hui Wang, Mei Xiao, Peijian Peng · 2017 · Cancer Management and Research
60. Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
    Indian Cooperative Oncology Network (ICON) · 2017 · Indian Journal of Cancer
61. Targeted Therapies for Non-Small Cell Lung Cancer
    Antonio Dello Russo, Christian Diego Rolfo, Francesco Passiglia, Rafael Rosell · 2015 · Current clinical pathology
62. Treatment Sequencing Strategies in Lung Cancer.
    Daniel Humberto Pozza, Ramon Andrade de Mello · 2022 · PubMed Central
63. The role of switch maintenance therapy in urothelial cancers
    Eun-mi Yu, Mythri Mudireddy, Rakesh Biswas, Jeanny B. Aragon‐Ching · 2023 · Therapeutic Advances in Urology
64. Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy
    Giuseppe Aprile, Francesco Giuliani, Stefania Eufemia Lutrino, Caterina Fontanella, Marta Bonotto, Karim Rihawi, Gianpiero Fasola · 2015 · Clinical Colorectal Cancer
65. Tumor Acquisition for Biomarker Research in Lung Cancer
    Marvaretta Miesha Stevenson, Jared Christensen, Debra Shoemaker, Traci Foster, William Thomas Barry, Betty Caroline Tong, Momen M. Wahidi, Scott L. Shofer, Michael Datto, Geoffrey S. Ginsburg et al. · 2014 · Cancer Investigation
66. Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
    Xinmin Zhao, Hui Yu, Jing Zhao, Xianghua Wu, Si Sun, Zhiguo Luo, Huijie Wang, Jie Qiao, Jianhua Chang, Jialei Wang · 2017 · Oncotarget
67. Safety of dose-reduced pemetrexed in patients with renal insufficiency
    Jordan Hill, Craig A. Vargo, Michael K. Smith, Jessica Streeter, David Paul Carbone · 2018 · Journal of Oncology Pharmacy Practice
68. First-line management of metastatic non-small cell lung cancer: An Indian perspective
    Nikhil Suresh Ghadyalpatil, Avinash Pandey, Iyer Krishnamani, Chilukuri Srinivas, Shabnam Jameela Rafiq, Sachin Hingmire, Venkata Nagarjuna Maturu, Ragotham Reddy, Kiran Kumar, K. Sreekanth et al. · 2019 · South Asian Journal of Cancer
69. Lung cancer in India: The rewards of REWERDS (REal World Evidence from Retrospective Data analysiS)
    Navneet Singh · 2020 · Current Problems in Cancer
70. Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
    Patricia Ann Young, Diana C. Márquez‐Garbán, Zorawar Singh Noor, Neda A. Moatamed, David A. Elashoff, Tristan Grogan, Tahmineh Romero, Hironobu Sasano, Ryoko Saito, Rebecca Rausch et al. · 2021 · JTO Clinical and Research Reports
71. Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision
    Xiayue Zhang, Henglu Cui, Xiaoyu Zhang, Zijian Zhang, Zhaoxiu Liu, Renfang Mao, Yihui Fan, Rong Sun, Miaomiao Chen · 2025 · Critical Reviews in Oncology/Hematology
72. Pembrolizumab as first-line treatment for non-small cell lung cancer—a game changer?
    Wolfram C. M. Dempke, Klaus Fenchel · 2016 · Translational Lung Cancer Research
73. The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China
    Qiang Shi, Shanlian Hu, Wesley E. Furnback, Gregory F. Guzauskas, Jiejing Shen, Bruce Wang · 2017 · ClinicoEconomics and Outcomes Research
74. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
    Liangzhe Zhang, Shugeng Gao, Jie He · 2017 · Drug Design Development and Therapy
75. You've Lived a Good Life
    Brendan F. Curley · 2015 · Journal of Clinical Oncology
76. Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato
    Francesco Grossi, Lucio Buffoni, Adolfo Gino Favaretto, Carlo Lucioni, S. Mazzi, Hector Josè Soto Parra · 2014 · PharmacoEconomics Italian Research Articles
77. Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
    Goyal Pankaj, Ullas Batra, Dinesh Chandra Doval, Parveen Jain, Upadhyay Kumar Amitabh, Prasanta Kumar Dash, Jain Akhil, Agarwal Mohit, Rajat Bajaj · 2016 · South Asian Journal of Cancer
78. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Toshirou Fukushima, Yuuki Wakatsuki, Takashi Kobayashi, Kei Sonehara, Kazunari Tateishi, Manabu Yamamoto, Takeshi Masubuchi, Fumiaki Yoshiike, Kazuya Hirai, Tsutomu Hachiya et al. · 2018 · Cancer Chemotherapy and Pharmacology
79. Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts
    Jingya Han, Yan Zhao, Xinming Zhao, Tuo Ma, Tiancheng Hao, Jiahui Liu, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang · 2019 · Investigational New Drugs
80. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
    Tarje Onsøien Halvorsen, Kristin Stokke, Kristin Toftaker Killingberg, Sunil Xavier Raj, Sveinung Sørhaug, Odd Terje Brustugun, Øystein Fløtten, Nina Helbekkmo, Kjersti Hornslien, Tesfaye Madebo et al. · 2020 · Acta Oncologica
81. In Spite of Curative Radical Pulmonary Procedures, Lesser Pulmonary Resection Shows More Favorable Prognosis in Surgically Treated NSCLC With Synchronous Isolated Cranial Oligometastases
    Erkan Kaba, Eyüp Halit Yardımcı, Jahnavi Kakuturu, Alper Toker · 2021 · Frontiers in Surgery
82. Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
    Xin Li, Jie Huang, Yao Qiu, Qianyun Zhang, Shao‐Yu Yang, Kan Wu, Jiaoli Wang, Limin Wang, Jian Ye, Shenglin Ma et al. · 2021 · Frontiers in Pharmacology
83. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
    Zhen He, Xiuli Yang, Tianjiang Ma, Qiumin Yang, Chenghui Zhang, Yunfang Chen, Pengyuan Wang, Armida D’Incecco, Giulio Metro, Shugo Uematsu et al. · 2022 · Translational Lung Cancer Research
84. Frontline Systemic Therapy With Pemetrexed–Platinum in Nonsquamous Non–Small-Cell Lung Cancer With Asymptomatic Brain Metastases
    Samer Alsidawi, Rekha T. Chaudhary, Nagla Abdel Karim · 2014 · American Journal of Therapeutics
85. Phase I Study of Carboplatin Combined with Pemetrexed for Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Hiroaki Takeoka, Kazuhiko Yamada, Koichi Azuma, Yoshiaki Zaizen, Fumie Yamashita, Tsukasa Yoshida, Yoshiko Naito, Yusuke Okayama, Maki Miyamoto, Tomoaki Hoshino · 2014 · Japanese Journal of Clinical Oncology
86. Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?
    Edurne Arriola, Álvaro Taus, David Casadevall · 2015 · World Journal of Clinical Oncology
87. Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
    Che-Hsing Li, Jiunn‐Liang Ko, Yu‐Ping Hsiao, Ming-Hung Tsai, Yen‐Chein Lai, I‐Lun Hsin, Yuting Kang, Gwo‐Tarng Sheu, Wea‐Lung Lin, Ming‐Fang Wu · 2021 · Cancer Management and Research
88. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
    Fangjian Shang, Boyuan Zhang, Shuo Kang · 2023 · Expert Review of Pharmacoeconomics & Outcomes Research
89. Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)
    Takaaki Tokito, Kazuhiko Yamada, Hidenobu Ishii, Yuichi Takiguchi, Go Saito, Koichi Minato, Hisao Imai, Hiroshi Tanaka, Satoru Miura, Kageaki Watanabe et al. · 2025 · Radiation Oncology
90. The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell Lung cancer
    Bas J.M. Peters, Esmée van Geffen, Doranne L. Hilarius, Stefan Böhringer, J. Zwaveling, Esther Dronkers, Cor H. van der Leest, Hans J.M. Smit · 2025 · Lung Cancer
91. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy
    Achim Rittmeyer · 2015 · Cancers
92. Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing
    M. Snee · 2014 · Clinical Oncology
93. Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
    Heidi M. Egloff, Aminah Jatoi · 2014 · Case Reports in Oncology
94. Modern Treatments in Advanced Non–Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study
    Olivier Carpentier, Lucia Selvaggi, Jérémie Jegu, Ashok Purohit, Nathalie Prim, Michel Velten, Élisabeth Quoix · 2015 · Clinical Lung Cancer
95. Molecular Targeted Therapy of Lung Cancer
    Yuichi Takiguchi · 2017 · Springer eBooks
96. Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China
    Yongji Lu, Ji Cheng, Ziyi Lin, Yuan Chen, Jianwei Xuan · 2017 · Journal of Medical Economics
97. Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
    Seung Sook Paik, In Kyoung Hwang, Myung Jae Park, Seung Hyeun Lee · 2018 · Tuberculosis & respiratory diseases
98. Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis
    Jianming Hu, Jiawei Hu, Xiaolan Liu, Long Li, Xue Bai · 2019 · Bioscience Reports
99. For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?
    Takanobu Sasaki, Toshiharu Tabata, Naruo Yoshimura · 2021 · Journal of Rural Medicine
100. Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
     Weichao Zhao, Minli Zhu, Ruijuan Wang, Zhaohui Tong · 2022 · Anti-Cancer Drugs